GlassScriptPhysician profile
Daisy C Arco
NPI 1083008320
$29,587.91
in general payments reported to CMS, 2019-2025
31 companies · $3,675 in 2025
The $3,675 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,661 · 2022: $13K · 2023: $7,765 · 2024: $2,748 · 2025: $3,675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,956 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,000 · Travel and Lodging: $179 · Education: $53.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,955.68 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,000.00 |
| Travel and Lodging | $178.64 |
| Education | $53.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $15,239.16 | 2021-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $3,168.13 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,013.22 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,464.08 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $996.07 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $833.74 | 2021-2025 | Verquvo, Lagevrio, Capvaxive |
| Glaxosmithkline, LLC. | $802.23 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $686.87 | 2021-2025 | |
| Lilly USA, LLC | $664.76 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $622.74 | 2022-2025 | |
| Corcept Therapeutics | $467.05 | 2024-2025 | Korlym |
| Daiichi Sankyo INC. | $370.82 | 2021-2023 | Injectafer |
| Esperion Therapeutics, INC. | $274.80 | 2021-2025 | Nexletol |
| Exact Sciences Corporation | $230.39 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $219.80 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $193.03 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $192.16 | 2025 | Caplyta |
| Astellas Pharma US INC | $183.86 | 2021-2025 | Veozah |
| Axsome Therapeutics, INC. | $175.36 | 2025 | Auvelity |
| Inspire Medical Systems, INC. | $171.65 | 2023 | Inspire |
| Dexcom, INC. | $147.30 | 2023-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.63 | 2021-2023 | Jardiance |
| Nabriva Therapeutics, Plc | $63.26 | 2021 | |
| Lundbeck LLC | $54.67 | 2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $51.85 | 2021 | |
| Abbott Laboratories | $44.74 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $37.06 | 2021-2024 | |
| Gilead Sciences, INC. | $35.76 | 2025 | |
| Eisai INC. | $23.71 | 2021 | |
| Si-Bone, INC. | $23.01 | 2021 | |
| Sumitomo Pharma America, INC. | $20.00 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daisy Arco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.